

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/137504/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Fiksinski, Ania M., Schneider, Maude, Zinkstok, Janneke, Baribeau, Danielle, Chawner, Samuel J. R. A. and Vorstman, Jacob A. S. 2021. Neurodevelopmental trajectories and psychiatric morbidity: lessons learned from the 22q11.2 deletion syndrome. *Current Psychiatry Reports* 23 , 13. [10.1007/s11920-021-01225-z](https://doi.org/10.1007/s11920-021-01225-z)

Publishers page: <http://doi.org/10.1007/s11920-021-01225-z>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



## TITLE PAGE

### TITLE

Neurodevelopmental trajectories and psychiatric morbidity: lessons learned from the 22q11.2 deletion syndrome.

### AUTHORS

*Ania M. Fiksinski (corresponding)*

1. Department of Psychiatry, Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
2. Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, and Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

Email: [A.M.Fiksinski@umcutrecht.nl](mailto:A.M.Fiksinski@umcutrecht.nl)

*Maude Schneider*

- 1) Clinical Psychology Unit for Intellectual and Developmental Disabilities, Faculty of Psychology and Educational Sciences, University of Geneva, Switzerland
- 2) Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven, Belgium

E-mail: [Maude.Schneider@unige.ch](mailto:Maude.Schneider@unige.ch)

*Janneke Zinkstok*

Department of Psychiatry & Brain Center, University Medical Center Utrecht, The Netherlands

E-mail: [J.R.Zinkstok@umcutrecht.nl](mailto:J.R.Zinkstok@umcutrecht.nl)

*Danielle Baribeau*

1. Department of Psychiatry, Hospital for Sick Children, Toronto, ON, Canada.
2. Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

E-mail: [danielle.baribeau@sickkids.ca](mailto:danielle.baribeau@sickkids.ca)

*Samuel J.R.A. Chawner*

1. Cardiff University Centre for Human Developmental Science, School of Psychology, Cardiff University, Cardiff, UK
2. MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University.

E-mail: [ChawnerSJ@cardiff.ac.uk](mailto:ChawnerSJ@cardiff.ac.uk)

*Jacob A.S. Vorstman*

1. The Centre for Applied Genomics, Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.
2. Department of Psychiatry, Hospital for Sick Children, Toronto, ON, Canada.
3. Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
4. Department of Psychiatry, Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Email: [Jacob.Vorstman@sickkids.ca](mailto:Jacob.Vorstman@sickkids.ca)

## **Declarations**

Funding: Personal grant (Ter Meulen) from the Royal Netherlands Academy of Arts and Sciences and the UMCU Strategic Network Development Grant (AMF); Personal grant from the Swiss National Science Foundation (SNF; grant number: PZ00P1\_174206) (MS); Wellcome Trust ISSF3 Fellowship Award (grant number: 204824/Z/16/Z) (SJRAC).

Conflicts of interest/competing interests: Jacob A.S. Vorstman serves as a consultant for NoBias Therapeutics Inc. for the design of a medication trial.

**Abstract (234 words)**

*Purpose of review.* The 22q11.2 deletion syndrome (22q11DS) is associated with a broad spectrum of neurodevelopmental phenotypes, and is the strongest known single genetic risk factor for schizophrenia. Compared to other rare structural pathogenic genetic variants, 22q11DS is relatively common and one of the most extensively studied. This review provides a state-of-the-art overview of current insights regarding associated neurodevelopmental phenotypes and potential implications for 22q11DS and beyond.

*Recent findings.* We will first discuss recent findings with respect to neurodevelopmental phenotypic expression associated with 22q11DS, including psychotic disorders, intellectual functioning, autism spectrum disorders, as well as their interactions. Second, we will address considerations that are important in interpreting these data and propose potential implications for both the clinical care for and the empirical study of individuals with 22q11DS. Third, we will highlight variable penetrance and pleiotropy with respect to neurodevelopmental phenotypes in 22q11DS. We will discuss how these phenomena are consistently observed in the context of virtually all rare pathogenic variants, and that they pose substantial challenges from both a clinical and a research perspective.

*Summary.* We outline how 22q11DS could be viewed as a genetic model for studying neurodevelopmental phenotypes. In addition, we propose that 22q11DS research can help elucidate mechanisms underlying variable expression and pleiotropy of neurodevelopmental phenotypes; insights that are likely relevant for 22q11DS and beyond; including for individuals with other rare pathogenic genetic variants and for individuals with idiopathic neurodevelopmental conditions.

**Keywords**

22q11.2 deletion; neurodevelopment, psychiatry, variable penetrance, copy number variant, genetic model

## **Introduction**

22q11.2 deletion syndrome (22q11DS) is caused by a heterozygous microdeletion of region 11.2 on the long arm of chromosome 22<sup>1</sup>. The prevalence of 22q11DS is currently estimated to range from 1 per 3000 to 1 per 6000 live births, with approximately 90-95% of cases not inherited from parents, i.e., arising from a *de novo* event<sup>2</sup>. 22q11DS is characterized by a complex and variable phenotype, including somatic, cognitive, and psychiatric manifestations. Shortly after the discovery of the genetic etiology of this syndrome in the 1990s<sup>1</sup>, studies emerged reporting an increased rate of schizophrenia and related psychotic disorders among individuals with 22q11DS<sup>4-7</sup>. These observations prompted several investigators across different sites to examine cognitive and behavioral characteristics of individuals from early childhood to adulthood. Taken together, these studies identified increased rates of a wide range of neurodevelopmental and psychiatric symptoms in this population beginning in early childhood<sup>8</sup>.

Starting over a decade ago, international collaborations such as the Psychiatric Genomic Consortium<sup>9</sup> began pooling case-control cohorts into large samples for genome-wide association studies for a range of psychiatric phenotypes. This approach demonstrated how large-scale international collaborations can successfully achieve certain scientific analyses that remain out of reach for independently working research groups. The International 22q11DS Brain Behavior Consortium (IBBC), funded by the US National Institute of Mental Health (NIMH), followed this example by bringing together 22 different sites across the world<sup>10</sup>. The aims of the IBBC included the identification of genetic mechanisms modifying the variable expression of schizophrenia in this syndrome, as well as further characterization of other behavioral and cognitive consequences of the syndrome. Following the same rationale and also funded by the NIMH, more recently the Genes To Mental Health (G2MH) Network was created ([www.genes2mentalhealth.com](http://www.genes2mentalhealth.com)), joining the efforts of numerous international researchers to examine these same questions in individuals with rare genomic variants associated with neurodevelopmental and psychiatric disorders (including but not limited to 22q11DS).

Here, we will provide an overview of the current understanding of both psychiatric and cognitive manifestations observed in individuals with 22q11DS, and what is known about the relationship between both domains. We will discuss potential implications for studies of and clinical care for individuals with 22q11DS and other rare variants, as well as highlight implications for idiopathic psychiatric disorders.

### **1. Psychiatric observations across the lifespan and associated considerations**

A landmark study by the IBBC<sup>10</sup> combined psychiatric data from multiple international sites on 1401 individuals with 22q11DS aged 6-69, and resulted in the largest study of psychiatric morbidity across the lifespan in 22q11DS<sup>11</sup>. ADHD (predominantly inattentive type rather than hyperactivity) is particularly common (in 37%) during childhood (6-12 years), with prevalence decreasing to 15% in adulthood. Autism spectrum disorders (ASD) are diagnosed in approximately 10-40% of

individuals with 22q11DS. Anxiety disorders are frequent across the lifespan (in 31%), but specific behavioral manifestations and symptoms of anxiety tend to evolve with age, with specific phobia, social phobia, and separation anxiety disorder being more prevalent in younger age groups and panic disorder more frequent among adults. Mood disorders are relatively uncommon in children, but their prevalence, especially of major depressive disorder, increases with age and reaches 20% in older adults ( $\geq 36$  years). Bipolar mood disorder, conduct disorder and substance use disorders do not appear to be increased in this population<sup>11,12</sup>. Few studies have studied comorbidity, but those that have, report frequent co-occurrence of two or more psychiatric disorders, particularly between ADHD and anxiety disorders, and between anxiety, mood, and schizophrenia<sup>11,13,14</sup>.

22q11DS is recognized as the highest known single genetic risk factor for schizophrenia, with approximately 20-25% of individuals developing this severe psychiatric illness by adulthood<sup>5</sup>. 22q11DS offers a unique opportunity to understand the neurodevelopmental pathophysiology of schizophrenia, including prospectively during early developmental stages<sup>15</sup>. Efforts have recently been devoted to characterizing early prodromal development of psychosis in 22q11DS, in line with the clinical high-risk (CHR) model of psychosis (for a review, see<sup>16</sup>). In a recent collaborative study which assessed 692 non-psychotic individuals with 22q11DS aged 6-55 years with the Structured Interview for Psychosis Risk Syndromes (SIPS;<sup>17</sup>), 54% of the sample was diagnosed with at least one psychotic symptoms (positive, negative, or disorganized) of moderate to high severity<sup>18</sup>. Importantly, clinical manifestations of schizophrenia in 22q11DS largely converges with that for idiopathic schizophrenia<sup>19-21</sup>. However some subtle differences have been reported; compared to other populations at risk for psychosis, individuals with 22q11DS are characterized by more severe negative symptoms of schizophrenia, including social anhedonia and avolition<sup>22-24</sup>. This suggests that 22q11DS might represent a good model to study negative symptoms that represent a yet unmet need in the management of schizophrenia<sup>25,26</sup>. The presence of CHR criteria (e.g., attenuated positive symptoms of psychosis above a certain frequency and duration threshold), has been shown to predict conversion to psychosis within 36 months in 27% of 22q11DS cases<sup>27</sup>, which is comparable to idiopathic schizophrenia<sup>28</sup>. However, the fact that 4.5% of individuals with 22q11DS converted to psychosis *without* meeting CHR criteria points to the need to identifying predictors beyond classical CHR criteria for psychotic disorders in this population<sup>27</sup>.

The prevalence rates of psychiatric manifestations in 22q11DS should be interpreted in light of ascertainment strategies, which vary across studies. Particularly those sites that recruit within a clinical setting may be more likely to include individuals who already have psychiatric symptoms. Further, the majority of studies include only individuals already known to have a diagnosis of 22q11DS, and will therefore not capture asymptomatic individuals who have not been referred for genetic testing. One of the few population-based epidemiological studies of 22q11DS used medical and genomic data from a Danish nation-wide registry, thereby capturing individuals in the population with 22q11DS who had not received a 22q11DS diagnosis within a clinical setting. Here, a similar pattern of psychiatric disorders was reported, but with lower prevalence rates (e.g., 7% for psychosis) compared to previous findings<sup>29</sup>. However, prevalence estimates in this study were derived from medical records, potentially underestimating the true prevalence of psychiatric conditions in the 22q11DS population. Also, medical record validity may be affected by diagnostic overshadowing and differences in regional diagnostic expertise and practices. Prevalence rates in

studies may also be influenced by the assessment methods used to query psychopathology. For example, differences in the reported rates of ASD between studies are likely partly explained by variability in the use of appropriate assessment methods for this condition<sup>30</sup>. In addition, in the general population the co-morbidity between ADHD and ASD symptoms is well-established<sup>31-33</sup> and may therefore also account for some of the variation in the reported rates of both disorders in 22q11DS across studies. Lastly, studies of 22q11DS have highlighted issues with current binary, categorical conceptualization of psychopathology, whereby disorders are either present or absent. The clinical reality for many individuals with 22q11DS is such that even in the absence of meeting criteria for a formal psychiatric diagnosis, clinically relevant psychiatric symptoms are present<sup>34,35</sup>.

The heterogeneity of cognitive, neurodevelopmental and psychiatric symptoms in 22q11DS mirrors the high degree of heterogeneity regarding *physical* manifestations, which can include wide-ranging combinations of brain, palate, cardiac and/or immune effects. Indeed, the observed phenotypic variability in 22q11DS is consistent with the phenomena of pleiotropy, incomplete penetrance and variable expressivity (see **glossary**), reported consistently in many rare CNV's<sup>36,37</sup>. Studies of psychiatric prevalence in 22q11DS raise important issues for the field of psychiatry. First, findings demonstrate that the risk conferred by one genetic variant is not necessarily specific. Indeed, 22q11DS is highly pleiotropic, conferring risk for several psychiatric conditions across the lifespan, that may or may not manifest independently of one another. Second, observations highlight that psychiatric phenotypes are not fully penetrant. For example, not every individual with 22q11DS will develop schizophrenia; indeed the majority will not. Third, the findings collectively raise issues surrounding current psychiatric classification, in that the range and co-morbidity of psychiatric phenotypic expressions associated with a specific genetic variant is oftentimes difficult to capture by the categorical classification. Many individuals with 22q11DS who do not meet all criteria for a specific psychiatric disorder, may nevertheless experience clinically distressing symptoms in that domain, highlighting the need for a more dimensional approach<sup>38,39</sup>.

## 2. 22q11.2 Deletion Syndrome as a model for studying neuropsychiatric conditions

22q11DS has been highlighted as a valuable model for studying neuropsychiatric conditions, as it is one of the strongest known risk factors for development of psychiatric illness. Increasing identification of 22q11DS prenatally or very early in life<sup>1</sup> permits in-depth prospective study of clinical and/or environmental longitudinal predictors, whilst minimizing ascertainment bias. As a high-risk group, it provides a magnifying lens to study how modifying factors such as additional genetic variability (including deletion size, breakpoints, structure of the intact chromosome, and other rare-rare or rare-common variant interactions) may contribute to highly variable clinical presentations. While results of such studies may be specific to 22q11DS, findings have implications beyond this specific disorder. In particular, 22q11DS can serve as a helpful example to understand the molecular mechanisms involved in the emergence of neuropsychiatric conditions; as a model to understand the early trajectories of neuropsychiatric disorders, in particular schizophrenia; and as a way elucidate mechanism that influence variable expression and pleiotropy in individuals with high-impact pathogenic genetic variants.

Regarding genetic modifiers, so far, data do not support a 1:1 relationship between any individual gene in the 22q11.2 region and a particular phenotype<sup>40</sup>. Deletion size and breakpoint location vary for a minority of subjects<sup>41-43</sup>, and may be associated with modest variability in clinical expression<sup>44</sup>, or brain structure<sup>45</sup>. Recently, research efforts have shifted towards studying two-hit or multi-hit hypotheses to explain variable penetrance in 22q11DS. Emerging data suggest that common and rare variants in the intact (non-deleted) chromosome may affect proclivity towards psychosis<sup>46</sup>, or Parkinson's disease in some families with 22q11DS<sup>47</sup>. For example, other rare CNVs elsewhere in the genome may confer additional risk for adverse outcomes in 22q11DS<sup>48,49</sup>. Broadly conceptualized, results may support a model of neuropsychiatric disorder whereby in the general population one's proclivity towards (or resilience against) specific manifestations (e.g., cognitive impairment, psychiatric symptoms) may be partly determined by one's (mostly inherited) profile of common genetic variants<sup>50</sup>. The vast majority of people in the general population do not express the more severe developmental or psychiatric phenotypes such as schizophrenia, ASD or intellectual disability. However, within the general population there are subsets of people who are affected by a rare, pathogenic variant, such as the 22q11.2 deletion. Over the past two decades, many studies have shown that in these individuals, the prevalence of severe phenotypes is increased compared to the general population, with variation in penetrance dependant on the specific genetic variant (e.g.,<sup>51</sup>). In any *individual* carrier of a specific rare pathogenic variant associated with developmental and psychiatric phenotypes, the expression of a specific phenotype is likely under the influence of the (mostly inherited) profile of common genetic variants<sup>52</sup> (**Figure 1**).

Within 22q11DS, the investigation of additional genetic modifiers has largely focused on the heterogeneity in psychosis outcomes. A proof-of-principle study using whole-genome sequencing (WGS) in a small but well-phenotyped sample of individuals with 22q11DS reported higher burden of additional rare mutations in protein-coding neurofunctional genes in individuals with 22q11DS diagnosed with schizophrenia, compared to those without schizophrenia.<sup>53</sup> Also, preliminary



findings indicate that individuals with 22q11DS and schizophrenia carry an excess of rare deletions that overlap with protein-coding genes when contrasted to 22q11DS individuals without schizophrenia.<sup>48</sup> One recent IBBC study included 519 unrelated patients and focused on genomic mechanisms that contribute to schizophrenia risk using WGS and microarray data.<sup>54</sup> The results showed that the same common genetic variation (summarized by the polygenic risk score (PRS) for schizophrenia) associated with schizophrenia in the general population, also modify schizophrenia expression in the context of the 22q11.2 deletion. Specifically, increased PRS in the subset of individuals with 22q11DS and schizophrenia was identified compared to those without schizophrenia.<sup>54</sup> At present, PRS is not suitable for individual or clinical prediction of psychosis risk,<sup>55</sup> but its potential is being widely investigated, including whether it may be used in multimodal prediction tools to help identify those at risk and tailor preventive and/or early intervention strategies to those at increased risk of developing psychosis.<sup>56</sup> Indeed, a recent study by the IBBC applied PRS for schizophrenia and PRS for intellectual function, both derived from studies in the general population, in a cohort of individuals with 22q11DS. The results showed that risk stratification is possible and yields results that are getting closer to those required for clinical use<sup>57</sup>.

The heterogeneity of the 22q11DS phenotype may be partly explained by the presence of regulatory genes in the 22q11.2 locus.<sup>58</sup> These regulatory genes may have variable impacts on gene expression outside the deleted region. For example, the 22q11.2 region contains several miRNAs.<sup>58</sup> An miRNA is a small, non-coding RNA molecule that regulates gene expression.<sup>59</sup> In addition, the DiGeorge Syndrome Critical Region Gene 8 (*DGCR8*), a gene located in the commonly deleted region, encodes a key miRNA processing protein.<sup>58</sup> Haploinsufficiency of the *DGCR8* gene has been shown to disrupt miRNA functioning,<sup>58,60,61</sup> and this could directly or indirectly affect the expression of neuropsychiatric risk genes elsewhere in the genome through altered up- or downregulated gene expression.<sup>60,61</sup> This hypothesis is supported by recent data from mouse studies suggesting that haploinsufficiency of *DGCR8* causes downregulation of the dopamine D<sub>2</sub> receptor in relevant brain regions for schizophrenia,<sup>60,61</sup> elevated *DRD1* expression,<sup>62</sup> and age-dependent ventricular enlargement.<sup>62</sup> These data may help explain etiological mechanisms underlying schizophrenia, especially the onset of psychotic symptoms in adolescence.

Environmental factors that are known to influence risk of psychiatric illness in the general population, e.g., trauma and stress, have not yet been extensively investigated in 22q11DS<sup>63,64</sup>. Large-scale prospective studies following well-phenotyped 22q11DS individuals that include environmental influences may provide information on the various mechanisms that play a role in brain-related phenotypes seen in 22q11DS.

Overall, 22q11DS presents an opportunity to study genetic and molecular mechanisms, as well as other clinical and environmental predictors and modifiers of neuropsychiatric expression over the lifespan, with potential implications for all neuropsychiatric conditions. Prospective, longitudinal studies of 22q11DS have helped identify markers for psychosis that precede onset of the illness, laying the foundations for development of preventive measures or early intervention.<sup>10,65</sup> A body of research (reviewed here<sup>66</sup>) has identified several cognitive and psychiatric factors in childhood that are associated with subsequent development of psychosis. Prenatal and neonatal factors may affect its longitudinal course to some extent<sup>67,68</sup>, and a recent study demonstrated a significant

association between parental anxiety and depression with psychopathology in offspring with 22q11DS<sup>69</sup>.

Findings from studies of 22q11DS may help guide patients and families and support optimal clinical care. However, it is becoming increasingly evident that they may also have broader implications: 22q11DS, as a high-risk group, provides a unique lens for identifying genetic, clinical and environmental factors that inform on the developmental trajectories of psychiatric conditions. Research in this field has potential for leading the way in identifying the mechanisms that contribute to the development of psychiatric disorders and for developing early interventions to prevent their onset.

### 3. Cognitive functioning and trajectories in 22q11DS

A core feature of 22q11DS is intellectual disability (i.e., significant impairments in cognitive and daily life skills, and IQ level below 70) with approximately 45% of patients falling in this category<sup>1, 71</sup>. However, this statistic of penetrance relies on a categorical view, thereby failing to capture the high variability of expression of the cognitive phenotype, both between – and within individuals. Decades of longitudinal studies of individuals with 22q11DS across all age groups have resulted in several insights with relevant ramifications to affected individuals and their as well as potential implications for studying populations with other pathogenic variants<sup>72,73</sup>.

In young children with 22q11DS, delayed milestones, both globally or, more specifically regarding language, are frequently observed<sup>74</sup>. Once standardized cognitive testing is feasible, intellectual functioning is most commonly evaluated within the range of mild intellectual disability (i.e., full scale IQ (FSIQ) 55-70) to borderline intellectual functioning (FSIQ between 70-85). A minority of patients have scores in the more extreme ends of the distribution, including around the minimum measurable IQ score (e.g., IQ = 40), as well as IQ-scores around 120<sup>75,76</sup>. On average, the deletion causes a negative shift of the IQ-distribution, of which the mean is 100 in the general population with a standard deviation of 15<sup>77</sup>. Hence, in 22q11DS, the IQ distribution has shifted ~2 SD to the left, while range and variance of the distribution otherwise are not altered in comparison to the IQ distribution in the general population (<sup>44</sup>, *Fiksinski et al., manuscript under review*).

In the general population, the effect of parental level of cognitive functioning on offspring cognitive functioning, also reflected in the role of common (shared) genetic variance for IQ, has been well established<sup>78</sup>. Evidence from studies of 22q11DS<sup>79,80</sup> and other pathogenic variants (e.g.,<sup>81</sup>) in support of a similar mechanism is emerging. A recent study reported that while IQ scores were ~30 points lower in 22q11DS patients compared to their unaffected parents, the distribution was significantly associated to the parental distribution (*Fiksinski et al., manuscript under review*). This is in line with the finding that common genetic variants associated with IQ, or proxies thereof, in the general population (IQ polygenic score<sup>82</sup>) are similarly important in shaping the cognitive phenotype in the context of the high-impact 22q11.2 deletion<sup>57</sup>.

While severe levels of intellectual disability are uncommon in children, they are more frequently observed in adults with 22q11DS<sup>74,76,83</sup> suggesting that cognitive abilities may not be stable in all individuals with 22q11DS<sup>84</sup>. Several studies, including one which studied the cognitive trajectories

of 718 individuals with 22q11DS, have reported that, overall, individuals with 22q11DS show a modest but significant decline in IQ throughout development<sup>71 84</sup> (*Fiksinski et al., manuscript under review*). These longitudinal IQ-data suggest that in childhood and adolescence, the observed typical decline in 22q11DS mostly reflects a slower pace in cognitive development compared to typically developing peers<sup>85</sup>. In adulthood, however, the observed decline suggests that individuals with 22q11DS are losing cognitive capacities at a faster pace compared to the general population<sup>77</sup>.

A subgroup of individuals with 22q11DS shows a decline in IQ in excess of what is expected even *within* this population. This IQ-decline, most prominent in Verbal IQ, is associated with a further elevated risk (compared to the baseline risk of ~25%<sup>1</sup>) of developing schizophrenia<sup>71</sup>. Such findings are consistent with longitudinal studies in the general population, which report that individuals who are at high risk or later developed a psychotic disorder showed increasing cognitive impairments over time, especially during adolescence<sup>86,87 88-90</sup>. There is emerging evidence that cognitive decline may in fact not only be a phenotypic precursor of full-blown schizophrenia, but may represent an earlier stage of the biological disease process and share part of the same genetic etiology. For example, a recent study of 540 idiopathic schizophrenia patients reported that those individuals with a significant cognitive decline had the highest schizophrenia polygenic risk score (SCZ-PRS), as compared to the individuals who remained cognitively stable and/or were already more severely cognitively impaired from an early age onwards<sup>91</sup>. A recent study from the 22q11DS IBBC reported findings in accordance with this. In this sample of 962 individuals with 22q11DS, SCZ-PRS was significantly elevated in individuals with cognitive decline compared to those without, indicating that common genetic risk factors for schizophrenia contribute to cognitive decline. At the same time, the polygenic score for IQ did not significantly differentiate between these two subgroups. Collectively, these findings suggest a genetic association between cognitive decline and schizophrenia<sup>57</sup>.

At the same time, observations from epidemiological studies indicate that the overall rate of psychopathology is increased in youth with idiopathic intellectual impairment<sup>92</sup>. This raises the question to what extent the prevalence of neurodevelopmental and psychiatric disorders in 22q11DS deviates from what is reported in unselected cohorts with intellectual impairment. Although different methodologies hinder the direct comparison of findings between different studies, the reported profiles of psychopathology between 22q11DS and IQ-matched individuals without 22q11DS, suggest that 22q11DS increases the risk of some psychiatric disorders (psychotic disorders, ASD, ADHD, anxiety and mood disorders), but not of others (disruptive disorders, substance use disorders) (**Figure 2**)<sup>8</sup>.

Another observation in this regard is that, with the exception of psychotic disorders, studies have found no correlation between cognitive level and the risk for psychiatric disorders in individuals with 22q11DS<sup>14,93</sup>, although recent evidence is emerging for an age-specific association between certain specific domains of cognition and psychopathology<sup>94</sup>. 22q11DS thus appears to have a specific impact on the behavioral phenotype, as well as on the cognitive phenotype. This has important implications for psychiatry, highlighting that increased risk of psychopathology cannot be solely explained as an unspecific consequence of intellectual impairment<sup>8</sup>.

#### **4. Implications for clinical care and research**

Clinical manifestations of 22q11DS are highly variable and can affect multiple organ systems<sup>1</sup>; practical guidelines have been published to assist clinicians with the management of these often complex presentations<sup>95</sup>. From a mental health care perspective, a focus on the genetically mediated increased risk for schizophrenia is understandable; not only because the association is strong, with approximately one in four to five individuals with 22q11DS developing this illness, but also because schizophrenia is among the most severe psychiatric conditions, with substantial impact on wellbeing<sup>96</sup> and long-term outcomes<sup>97</sup>, including life expectancy<sup>98</sup>. Historically, schizophrenia was the first reported specific psychiatric phenotype in individuals with 22q11DS<sup>5-7,99</sup>. Subsequent studies progressively revealed a broader scope of associated psychopathology, including anxiety and mood disorders, as well as neurodevelopmental disorders identifiable early in life, such as language disorders, intellectual disability, specific learning disorders, ADHD and ASD.

Each of these conditions warrants appropriate diagnostic attention as well as optimal clinical guidance and treatment whenever possible. However, the psychiatric multi-morbidity observed in many patients with 22q11DS carries a real danger of initiating multiple more or less independent treatment(s) based on an individual consideration of each diagnosis. Such fragmented approaches are understandable and probably at least partly also relate to how mental health care is organized. However, from the standpoint of good clinical practice, a holistic approach is likely superior, as it integrates developmental, cognitive and behavioral aspects and includes a dimensional view on symptoms rather than relying exclusively on diagnostic categories<sup>100</sup>. It is likely that future developments in data-driven network approaches<sup>101</sup> - which strive to understand mental health issues as a set of inter-connected signs and symptoms - once applied to clinical practice, will contribute to understanding the clinical presentation of complex disorders in a more holistic approach. Importantly, such perspective decreases the risk of overshadowing, where psychopathology remains undiagnosed because relevant psychiatric symptoms are wrongly attributed to the cognitive impairment or the presence of another comorbid psychiatric condition<sup>102,103</sup>. A holistic view also takes into account potential relations between the various components of the clinical presentation. For example, deficits in attention and planning may be taken to indicate the possibility of ADHD when considered independently, but when viewed in the context of co-morbid developmental delay may be appropriate for mental age, given that the DSM-5 requires symptoms to be "inconsistent with developmental level"<sup>104</sup>. Other examples include high levels of anxiety which may sometimes be due to an uneven distribution of cognitive abilities<sup>105</sup> in the face of unrealistically high academic expectations; or social withdrawal, which may be understood in the context of increasing complexity of social demands gradually exceeding limited social and communicative skills. Importantly, in these examples, it is not the level of impairment in and by itself, but rather the extent to which they are out of sync with environmental demands and expectations. Indeed, studies indicate that the increased rates of psychopathology in 22q11DS are not an unspecific consequence of cognitive impairment in this population<sup>8</sup>. However, this may be different with regard to schizophrenia. Similar as to observations in the general population<sup>87,106,107</sup>, studies in 22q11DS show that both low intellectual ability early in life and a subsequent decline thereof are associated with increased risk of schizophrenia<sup>10</sup>. For clinicians, these observations

indicate the importance of careful monitoring of cognitive and social abilities, with attention to the (fluctuating) balance between individual abilities on the one hand, and environmental expectations on the other.

Research into 22q11DS aims to improve the quality of care for individuals and their families. However, research in this patient group has important ramifications for other clinical groups. The strong association with schizophrenia combined with the ability to make a genetic diagnosis early in life provides an unprecedented opportunity to study schizophrenia in an etiologically homogeneous subpopulation, starting early in development. This lifespan perspective is consistent with a neurodevelopmental perspective of schizophrenia, but also for other conditions associated with 22q11DS (e.g., anxiety disorders, ADHD, ASD). In the past fifteen years or so, an increasing number of rare pathogenic genetic variants are being discovered, associated with high risks of neurodevelopmental and psychiatric outcomes<sup>108</sup>. Against this backdrop, 22q11DS is emerging as one of a few “least rare” among these rare genetic conditions, thereby allowing sufficiently powered studies to start examining the mechanisms underlying variable penetrance and pleiotropy, all of which are invariably observed in relation to rare genetic disorders and pose formidable challenges to both clinicians and researchers. Clinical care practices developed for 22q11DS may lead the way for clinical care of newly identified neuropsychiatric variants. As genetic testing increases within psychiatric settings, the lessons learnt from 22q11DS will become ever more vital.

## **Conclusions**

Since its earliest clinical descriptions of 22q11DS in the 1960s<sup>109</sup>, a vast body of research continues to contribute to our current understanding of this complex, multi-system genetic disorder. Since the 1990s, the increased risk for schizophrenia became clear, followed by the observations of other psychopathology, including developmental disorders identifiable early in life. Subsequent and more recent studies are starting to elucidate the relations between different domains of psychopathology and the role of cognition. There is an increasing awareness to view these components in a developmental, lifespan perspective and the need to consider symptoms not only in a categorical, but also in a dimensional, quantitative framework. These changing perspectives allow for a more holistic diagnostic approach and treatment for this population, but are also vital for research. Studies in the 22q11DS population continue to contribute to our understanding of schizophrenia, other developmental disorders, variable penetrance and expressivity, and pleiotropy. All of these are challenging phenomena that are relevant to neuropsychiatric outcomes in individuals with the 22q11.2 deletion as well as other rare pathogenic variants, and to the understanding of the expression of, and mechanisms underlying, neuropsychiatric disorders more broadly.

## Glossary:

**Pleiotropy** refers to the concept that one gene can simultaneously influence more than one distinct trait/ phenotype, downstream effect, or organ. For example, cardiac malformations and schizophrenia are considered true pleiotropic manifestations in 22q11DS because they were shown to occur independently from each other<sup>19</sup>. Within the domain of neuropsychiatric manifestations, it is sometimes difficult to determine if two different symptoms are the expression of “true” pleiotropy or rather reflect “pseudopleiotropy” (phenotypes that are observed as separate manifestations, whereas in reality they represent the same pathological process) (for a more comprehensive discussion on this topic, see <sup>8</sup>).

**Incomplete, or variable, penetrance** refers to the observations that not all individuals carrying a certain genetic risk variant will display the phenotype. For example, the penetrance of schizophrenia in 22q11DS is 25%.

A closely related, but distinct concept is **variable expressivity**. Since variable expressivity refers to the observed variations in the severity of a given phenotype, it presupposes a dimensional measure of the trait. For example, the impact of the 22q11.2 deletion on intellectual ability can be expressed dimensionally as IQ; as such it shows a pattern consistent with variable expressivity. However, when considering IQ level as a categorical trait, for example separating those with intellectual disability (ID; here defined as IQ below 70) from those without, one could say that in 22q11DS, the penetrance of ID is incomplete, with approximately 45% of individuals having an IQ in the range of ID.

## Highlighted references :

*Fiksinski, A.M., et al. Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome. American journal of medical genetics. Part A* **176**, 2182-2191 (2018).

One of the focuses of this review article is the detailed discussion of factors that potentially impact the prevalence rates reported for neuropsychiatric outcomes in individuals with 22q11DS. These factors include ascertainment and assessment biases, pleiotropy, age-dependency of phenotypic expression, and the frequently observed subthreshold expression of symptoms.

*Chawner, S., et al. Genotype-phenotype associations in children with copy number variants associated with high neuropsychiatric risk in the UK (IMAGINE-ID): a case-control cohort study. Lancet Psychiatry* **6**, 493-505 (2019).

This case-control study studied neurodevelopmental phenotypes in children with one of 13 different copy number variants (CNVs). There were subtle quantitative and qualitative differences in the impact on neurodevelopment between the CNVs. Importantly, the risk for neuropsychiatric outcomes conferred by the CNVs was pleiotropic; affecting multiple neurodevelopmental processes and underlining that different neurodevelopmental phenotypes should be studied synergistically, rather than merely as entirely independent constructs.

*Cleynen, I., et al. Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular psychiatry* (2020).

This study used whole-genome sequencing data from 519 unrelated individuals with 22q11DS. Findings revealed, for the first time, that the polygenic score for schizophrenia was elevated in the individual with 22q11DS and schizophrenia, as compared to individuals with 22q11DS but not psychotic illness. Thus, in addition to the deletion conferring a substantially increased risk for schizophrenia in these individuals, the risk is further elevated by common polygenic risk factors that contribute to schizophrenia in the general population.

*Davies, R.W., Fiksinski, A.M., et al. Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 Deletion Syndrome. Nature Medicine, in press* (2020).

This study of 962 individuals with 22q11DS demonstrated that common genetic variation associated with schizophrenia and IQ in the general population impacts expression of these respective phenotypes in the context of a 22q11.2 deletion as well, informing on the mechanisms underlying the observed variable penetrance of these phenotypes. Further, the findings revealed that polygenic scores for schizophrenia and IQ can be used to substantially improve risk stratification in the context of the presence of a high-impact genetic variant that is associated with an *a priori* elevated risk for these phenotypes.

*Murray, G.K., et al. Could Polygenic Risk Scores Be Useful in Psychiatry?: A Review. JAMA psychiatry* (2020).

This review discussed the potential use of polygenic risk scores in psychiatry and elaborates on important associated considerations. One of the main conclusions is that, when combined with information from molecular, clinical, and lifestyle metrics, polygenic scores will likely contribute to

risk assessment in clinical psychiatry. The importance of considering such advances in an ethical framework as well as in the context of realistic expectations is highlighted.



## Bibliography

1. McDonald-McGinn, D.M., *et al.* 22q11.2 deletion syndrome. *Nat Rev Dis Primers* **1**, 15071-15071 (2015).
2. Oskarsdóttir, S., Vujic, M. & Fasth, A. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. *Archives of disease in childhood* **89**, 148-151 (2004).
4. Bassett, A.S., *et al.* 22q11 deletion syndrome in adults with schizophrenia. *Am.J.Med.Genet.* **81**, 328-337 (1998).
5. Murphy, K.C., Jones, L.A. & Owen, M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. *Archives of general psychiatry* **56**, 940-945 (1999).
6. Pulver, A.E., *et al.* Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. *J.Nerv.Ment.Dis.* **182**, 476-478 (1994).
7. Shprintzen, R.J., Goldberg, R., Golding-Kushner, K.J. & Marion, R.W. Late-onset psychosis in the velo-cardio-facial syndrome. *Am.J.Med.Genet.* **42**, 141-142 (1992).
8. Fiksinski, A.M., *et al.* Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome. *American journal of medical genetics. Part A* **176**, 2182-2191 (2018).
9. Sullivan, P.F. The psychiatric GWAS consortium: big science comes to psychiatry. *Neuron* **68**, 182-186 (2010).
10. Gur, R.E., *et al.* A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium. *Molecular psychiatry* **22**, 1664-1672 (2017).
11. Schneider, M., *et al.* Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. *Am J Psychiatry* **171**, 627-639 (2014).
12. Vingerhoets, C., *et al.* Low prevalence of substance use in people with 22q11.2 deletion syndrome. *The British journal of psychiatry : the journal of mental science*, 1-7 (2019).
13. Malecki, S.L., *et al.* A genetic model for multimorbidity in young adults. *Genetics in medicine : official journal of the American College of Medical Genetics* **22**, 132-141 (2020).
14. Niarchou, M., *et al.* Psychopathology and cognition in children with 22q11.2 deletion syndrome. *The British journal of psychiatry : the journal of mental science* **204**, 46-54 (2014).
15. Insel, T.R. Rethinking schizophrenia. *Nature* **468**, 187-193 (2010).
16. Fusar-Poli, P., *et al.* Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. *JAMA psychiatry* (2020).
17. McGlashan, T., Walsh, B. & Woods, S. *The psychosis-risk syndrome: handbook for diagnosis and follow-up*, (Oxford University Press, New York, 2010).
18. Weisman, O., *et al.* Subthreshold Psychosis in 22q11.2 Deletion Syndrome: Multisite Naturalistic Study. *Schizophr Bull* **43**, 1079-1089 (2017).
19. Bassett, A.S. & Chow, E.W. Schizophrenia and 22q11.2 deletion syndrome. *Curr Psychiatry Rep* **10**, 148-157 (2008).
20. Bassett, A.S., *et al.* The schizophrenia phenotype in 22q11 deletion syndrome. *The American journal of psychiatry* **160**, 1580-1586 (2003).
21. Monks, S., *et al.* Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome. *Schizophr Res* **153**, 231-236 (2014).
22. Armando, M., *et al.* Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a comparison of prodromal psychotic symptoms and general functioning. *Schizophr Res* **139**, 151-156 (2012).
23. Mekori-Domachevsky, E., *et al.* Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study. *Schizophr Res* **188**, 42-49 (2017).

24. Tang, S.X., *et al.* Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated. *Psychol Med* **44**, 1267-1277 (2014).
25. Citrome, L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. *The Journal of clinical psychiatry* **75 Suppl 1**, 21-26 (2014).
26. Schneider, M., *et al.* Prevalence, course and psychosis-predictive value of negative symptoms in 22q11.2 deletion syndrome. *Schizophr Res* **206**, 386-393 (2019).
27. Schneider, M., *et al.* Ultra high risk status and transition to psychosis in 22q11.2 deletion syndrome. *World psychiatry : official journal of the World Psychiatric Association* **15**, 259-265 (2016).
28. Fusar-Poli, P., *et al.* The psychosis high-risk state: a comprehensive state-of-the-art review. *JAMA Psychiatry* **70**, 107-120 (2013).
29. Hoeffding, L.K., *et al.* Risk of Psychiatric Disorders Among Individuals With the 22q11.2 Deletion or Duplication: A Danish Nationwide, Register-Based Study. *JAMA psychiatry* **74**, 282-290 (2017).
30. Schneider, M., *et al.* Psychiatric Disorders From Childhood to Adulthood in 22q11.2 Deletion Syndrome: Results From the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. *The American journal of psychiatry* (2014).
31. Baribeau, D.A., *et al.* Examining and comparing social perception abilities across childhood-onset neurodevelopmental disorders. *Journal of the American Academy of Child and Adolescent Psychiatry* **54**, 479-486 e471 (2015).
32. Krakowski, A.D., *et al.* Inattention and hyperactive/impulsive component scores do not differentiate between autism spectrum disorder and attention-deficit/hyperactivity disorder in a clinical sample. *Mol Autism* **11**, 28 (2020).
33. Rommelse, N.N., Franke, B., Geurts, H.M., Hartman, C.A. & Buitelaar, J.K. Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. *European child & adolescent psychiatry* **19**, 281-295 (2010).
34. Vorstman, J.A.S., *et al.* The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. *Journal of the American Academy of Child and Adolescent Psychiatry* **45**, 1104-1113 (2006).
35. Chawner, S., *et al.* A Genetics-First Approach to Dissecting the Heterogeneity of Autism: Phenotypic Comparison of Autism Risk Copy Number Variants. *medRxiv*, 2020.2001.2014.20017426 (2020).
36. Bassett, A.S., Scherer, S.W. & Brzustowicz, L.M. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. *Am J Psychiatry* **167**, 899-914 (2010).
37. Vorstman, J.A. & Ophoff, R.A. Genetic causes of developmental disorders. *Current opinion in neurology* **26**, 128-136 (2013).
38. Baker, K. & Vorstman, J.A. Is there a core neuropsychiatric phenotype in 22q11.2 deletion syndrome? *Current opinion in neurology* **25**, 131-137 (2012).
39. Doherty, J.L. & Owen, M.J. Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice. *Genome Med* **6**, 29 (2014).
40. Motahari, Z., Moody, S.A., Maynard, T.M. & LaMantia, A.S. In the line-up: deleted genes associated with DiGeorge/22q11.2 deletion syndrome: are they all suspects? *J Neurodev Disord* **11**, 7 (2019).
41. Vervoort, L., *et al.* Atypical chromosome 22q11.2 deletions are complex rearrangements and have different mechanistic origins. *Human Molecular Genetics* **28**, 3724-3733 (2019).
42. Burnside, R.D. 22q11.21 Deletion Syndromes: A Review of Proximal, Central, and Distal Deletions and Their Associated Features. *Cytogenet Genome Res* **146**, 89-99 (2015).

43. Guo, T., *et al.* Deletion size analysis of 1680 22q11.2DS subjects identifies a new recombination hotspot on chromosome 22q11.2. *Human molecular genetics* **27**, 1150-1163 (2018).
44. Zhao, Y., *et al.* Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects. *American journal of medical genetics. Part A* **176**, 2172-2181 (2018).
45. Ching, C.R.K., *et al.* Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness. *appiajp201919060583* (2020).
46. Michaelovsky, E., *et al.* Risk gene-set and pathways in 22q11.2 deletion-related schizophrenia: a genealogical molecular approach. *Translational Psychiatry* **9**, 15 (2019).
47. Butcher, N.J., *et al.* Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. *PLoS One* **12**, e0173944 (2017).
48. Bassett, A.S., *et al.* Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome. *The American journal of psychiatry* **174**, 1054-1063 (2017).
49. Cohen, J.L., *et al.* 22q and two: 22q11.2 deletion syndrome and coexisting conditions. *Am J Med Genet A* **176**, 2203-2214 (2018).
50. Niemi, M.E.K., *et al.* Common genetic variants contribute to risk of rare severe neurodevelopmental disorders. *Nature* **562**, 268-271 (2018).
51. Huguet, G., *et al.* Measuring and Estimating the Effect Sizes of Copy Number Variants on General Intelligence in Community-Based Samples. *JAMA Psychiatry* **75**, 447-457 (2018).
52. Chawner, S., *et al.* Genotype-phenotype associations in children with copy number variants associated with high neuropsychiatric risk in the UK (IMAGINE-ID): a case-control cohort study. *Lancet Psychiatry* **6**, 493-505 (2019).
53. Merico, D., *et al.* Whole-Genome Sequencing Suggests Schizophrenia Risk Mechanisms in Humans with 22q11.2 Deletion Syndrome. *G3 (Bethesda)* **5**, 2453-2461 (2015).
54. Cleynen, I., *et al.* Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. *Molecular psychiatry* (2020).
55. Binder, E.B. Polygenic Risk Scores in Schizophrenia: Ready for the Real World? *Am J Psychiatry* **176**, 783-784 (2019).
56. Murray, G.K., *et al.* Could Polygenic Risk Scores Be Useful in Psychiatry?: A Review. *JAMA psychiatry* (2020).
57. Davies, R.W., *et al.* Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 Deletion Syndrome. *Nature Medicine, in press* (2020).
58. Merico, D., *et al.* MicroRNA Dysregulation, Gene Networks, and Risk for Schizophrenia in 22q11.2 Deletion Syndrome. *Front Neurol* **5**, 238 (2014).
59. Mahmoudi, E. & Cairns, M.J. MiR-137: an important player in neural development and neoplastic transformation. *Mol Psychiatry* **22**, 44-55 (2017).
60. Chun, S., *et al.* Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models. *Science* **344**, 1178-1182 (2014).
61. Chun, S., *et al.* Thalamic miR-338-3p mediates auditory thalamocortical disruption and its late onset in models of 22q11.2 microdeletion. *Nat Med* **23**, 39-48 (2017).
62. Eom, T.Y., *et al.* Schizophrenia-related microdeletion causes defective ciliary motility and brain ventricle enlargement via microRNA-dependent mechanisms in mice. *Nat Commun* **11**, 912 (2020).
63. Armando, M., *et al.* Coping Strategies Mediate the Effect of Stressful Life Events on Schizotypal Traits and Psychotic Symptoms in 22q11.2 Deletion Syndrome. *Schizophrenia bulletin* **44**, S525-S535 (2018).


64. Mayo, D., Bolden, K.A., Simon, T.J. & Niendam, T.A. Bullying and psychosis: The impact of chronic traumatic stress on psychosis risk in 22q11.2 deletion syndrome - a uniquely vulnerable population. *J Psychiatr Res* **114**, 99-104 (2019).
65. Sommer, I.E., *et al.* Early interventions in risk groups for schizophrenia: what are we waiting for? *NPJ Schizophr* **2**, 16003 (2016).
66. Tang, S. & Gur, R. Longitudinal perspectives on the psychosis spectrum in 22q11. 2 deletion syndrome. *American journal of medical genetics. Part A* (2017).
67. Bassett, A.S., Costain, G. & Marshall, C.R. Neuropsychiatric aspects of 22q11.2 deletion syndrome: considerations in the prenatal setting. *Prenat Diagn* **37**, 61-69 (2017).
68. Schindewolf, E., *et al.* Expanding the fetal phenotype: Prenatal sonographic findings and perinatal outcomes in a cohort of patients with a confirmed 22q11.2 deletion syndrome. *Am J Med Genet A* **176**, 1735-1741 (2018).
69. Sandini, C., Schneider, M., Eliez, S. & Armando, M. Association Between Parental Anxiety and Depression Level and Psychopathological Symptoms in Offspring With 22q11.2 Deletion Syndrome. *Front Psychiatry* **11**, 646 (2020).
71. Vorstman, J.A., *et al.* Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. *JAMA psychiatry* **72**, 377-385 (2015).
72. Tang, S.X. & Gur, R.E. Longitudinal perspectives on the psychosis spectrum in 22q11. 2 deletion syndrome. *American Journal of Medical Genetics Part A* (2017).
73. Chawner, S.J., *et al.* Childhood cognitive development in 22q11. 2 deletion syndrome: case-control study. *The British Journal of Psychiatry, bjp.* bp. 116.195651 (2017).
74. Swillen, A., *et al.* Neuropsychological, learning and psychosocial profile of primary school aged children with the velo-cardio-facial syndrome (22q11 deletion): evidence for a nonverbal learning disability? *Child Neuropsychol* **5**, 230-241 (1999).
75. Chow, E.W., Watson, M., Young, D.A. & Bassett, A.S. Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. *Schizophrenia Research* **87**, 270-278 (2006).
76. De Smedt, B., *et al.* Intellectual abilities in a large sample of children with Velo-Cardio-Facial Syndrome: an update. *J Intellect Disabil Res* **51**, 666-670 (2007).
77. Wechsler, D. *Wechsler Adult Intelligence Scale-Fourth Edition.*, (Pearson, San Antonio, TX, 2008).
78. Plomin, R. & Deary, I.J. Genetics and intelligence differences: five special findings. *Mol Psychiatry* **20**, 98-108 (2015).
79. Klaassen, P., *et al.* Explaining the variable penetrance of CNVs: Parental intelligence modulates expression of intellectual impairment caused by the 22q11.2 deletion. *American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* **171**, 790-796 (2016).
80. Olszewski, A.K., Radoeva, P.D., Fremont, W., Kates, W.R. & Antshel, K.M. Is child intelligence associated with parent and sibling intelligence in individuals with developmental disorders? An investigation in youth with 22q11.2 deletion (velo-cardio-facial) syndrome. *Res Dev Disabil* **35**, 3582-3590 (2014).
81. Moreno-De-Luca, A., *et al.* The role of parental cognitive, behavioral, and motor profiles in clinical variability in individuals with chromosome 16p11.2 deletions. *JAMA Psychiatry* **72**, 119-126 (2015).
82. Davies, G., *et al.* Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. *Nat Commun* **9**, 2098 (2018).
83. Evers, L.J., De Die-Smulders, C.E., Smeets, E.E., Clerkx, M.G. & Curfs, L.M. The velo-cardio-facial syndrome: the spectrum of psychiatric problems and cognitive deterioration at adult age. *Genet Couns* **20**, 307-315 (2009).

84. Duijff, S.N., *et al.* Cognitive development in children with 22q11.2 deletion syndrome. *The British journal of psychiatry : the journal of mental science* **200**, 462-468 (2012).
85. Swillen, A. & McDonald-McGinn, D. Developmental trajectories in 22q11.2 deletion. *American Journal of Medical Genetics Part C: Seminars in Medical Genetics* **169**, 172-181 (2015).
86. MacCabe, J.H., *et al.* Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males. *JAMA Psychiatry* **70**, 261-270 (2013).
87. Mollon, J., David, A.S., Zammit, S., Lewis, G. & Reichenberg, A. Course of Cognitive Development From Infancy to Early Adulthood in the Psychosis Spectrum. *JAMA psychiatry* **75**, 270-279 (2018).
88. Harvey, P.D., Bowie, C.R. & Friedman, J.I. Cognition in schizophrenia. *Curr Psychiatry Rep* **3**, 423-428 (2001).
89. Keefe, R.S.E. & Kahn, R.S. Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia. *JAMA Psychiatry* **74**, 535-536 (2017).
90. Kahn, R.S. & Keefe, R.S. Schizophrenia is a cognitive illness: time for a change in focus. *JAMA Psychiatry* **70**, 1107-1112 (2013).
91. Dickinson, D., *et al.* Distinct Polygenic Score Profiles in Schizophrenia Subgroups With Different Trajectories of Cognitive Development. *Am J Psychiatry*, appiajp201919050527 (2019).
92. Einfeld, S.L., Ellis, L.A. & Emerson, E. Comorbidity of intellectual disability and mental disorder in children and adolescents: a systematic review. *J Intellect Dev Disabil* **36**, 137-143 (2011).
93. Evers, L.J., *et al.* Psychopathology in adults with 22q11 deletion syndrome and moderate and severe intellectual disability. *J Intellect Disabil Res* **58**, 915-925 (2014).
94. Morrison, S., *et al.* Cognitive deficits in childhood, adolescence and adulthood in 22q11.2 deletion syndrome and association with psychopathology. *Transl Psychiatry* **10**, 53 (2020).
95. Bassett, A.S., *et al.* Practical guidelines for managing patients with 22q11.2 deletion syndrome. *J Pediatr* **159**, 332-339 e331 (2011).
96. Millier, A., *et al.* Humanistic burden in schizophrenia: a literature review. *Journal of psychiatric research* **54**, 85-93 (2014).
97. Davidson, M., *et al.* A Nation-Wide Study on the Percentage of Schizophrenia and Bipolar Disorder Patients Who Earn Minimum Wage or Above. *Schizophrenia bulletin* **42**, 443-447 (2016).
98. Hjorthoj, C., Sturup, A.E., McGrath, J.J. & Nordentoft, M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. *Lancet Psychiatry* **4**, 295-301 (2017).
99. Bassett, A.S. & Chow, E.W. 22q11 deletion syndrome: a genetic subtype of schizophrenia. *Biol.Psychiatry* **46**, 882-891 (1999).
100. Baker, K. & Vorstman, J.A. Is there a core neuropsychiatric phenotype in 22q11.2 deletion syndrome? *Current opinion in neurology* **25**, 131-137 (2012).
101. Boccaletti, S., Latora, V., Moreno, Y., Chavez, M. & Hwang, D.U. Complex networks: Structure and dynamics. *Physics Reports* **424**, 175-308 (2006).
102. Rush, K.S., Bowman, L.G., Eidman, S.L., Toole, L.M. & Mortenson, B.P. Assessing psychopathology in individuals with developmental disabilities. *Behav Modif* **28**, 621-637 (2004).
103. Reiss, S., Levitan, G.W. & Szyszko, J. Emotional disturbance and mental retardation: diagnostic overshadowing. *Am J Ment Defic* **86**, 567-574 (1982).

104. American\_Psychiatric\_Association & DSM\_Task\_Force. Diagnostic and statistical manual of mental disorders : DSM-5. (2013).
105. Swillen, A. & McDonald-McGinn, D. Developmental trajectories in 22q11.2 deletion. *American journal of medical genetics. Part C, Seminars in medical genetics* **169**, 172-181 (2015).
106. Woodberry, K.A., Giuliano, A.J. & Seidman, L.J. Premorbid IQ in schizophrenia: a meta-analytic review. *The American journal of psychiatry* **165**, 579-587 (2008).
107. Reichenberg, A., *et al.* Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. *The American journal of psychiatry* **167**, 160-169 (2010).
108. Malhotra, D. & Sebat, J. CNVs: Harbingers of a Rare Variant Revolution in Psychiatric Genetics. *Cell* **148**, 1223-1241 (2012).
109. DiGeorge, A. A new concept of the cellular base of immunology. *J. Pediatr.* **67**, 907-908 (1965).

## Figures

**Figure 1.** High-impact genetic variants exert their impact on neuropsychiatric phenotypes in the context of common genetic variation.



*In the general population (left), the cumulative burden of common genetic variants that impact neurodevelopment are distributed (blue) such that only a very small proportion of individuals will be above the phenotype expression threshold (red), and develop a neurodevelopmental disorder. In individuals with a high-impact variant (right), such as the 22q11.2 deletion, the same genetic background factors influence risk for neuropsychiatric outcomes. However, due to the elevated baseline risk conferred by the variant, a much larger proportion will express the phenotype.*

**Figure 2.** Prevalence rates of psychopathology in youth with 22q11DS compared to youth with idiopathic intellectual impairment and the general population.




Figure derived from table from Fiksinski et al., *Am J Med Gen A* (2018).

Data for youth with 22q11DS derived from (Schneider et al., 2014) (805 individuals; note that the prevalence rate of psychosis is lower than the typically reported 20-25% in adults with 22q11DS, as these data only include youth).

Data for youth with idiopathic intellectual impairment derived from (Emerson & Hatton, 2007) (641 individuals, age range 5 to 16 years, intellectual impairment based on parental/teacher report, most individuals estimated at a level of mild intellectual disability, the numbers represent point prevalence (i.e., symptoms present during the month – half year preceding the assessment); psychotic disorder not specifically reported.

Data for general population youth derived from cohorts including both children and adolescents with exact age ranging vary between the different studies.